Publications by authors named "P E Lovat"

Accurate prognostication guides optimal clinical management in skin cancer. Merkel cell carcinoma (MCC) is the most aggressive form of skin cancer that often presents in advanced stages and is associated with poor survival rates. There are no personalized prognostic tools in use in MCC.

View Article and Find Full Text PDF

Background: Merkel cell carcinoma (MCC) is a highly aggressive cutaneous malignancy for which accurate prognostication is necessary to support clinical management.

Objective: (1) To determine which survival endpoint-disease-specific death (DSD) or overall survival (OS)-was better stratified by MCC American Joint Cancer Committee eighth edition staging. (2) To develop a multivariable model for enhanced MCC survival predictions.

View Article and Find Full Text PDF

Alternative 3-dimensional (3D) skin models that replicate in vivo human skin are required to investigate important events during wound healing, such as collective cell migration, epidermal layer formation, dermal substrate formation, re-epithelialisation and collagen production. In this study, a matched human 3D skin equivalent model (3D-SEM) was developed from human skin cells (fibroblast and keratinocytes), characterised using haematoxylin and eosin, immunofluorescence staining and microRNA profiling. The 3D-SEM was then functionally tested for its use in wound healing studies.

View Article and Find Full Text PDF

Selective degradation of damaged mitochondria by autophagy (mitophagy) is proposed to play an important role in cellular homeostasis. However, the molecular mechanisms and the requirement of mitochondrial quality control by mitophagy for cellular physiology are poorly understood. Here, we demonstrated that primary human cells maintain highly active basal mitophagy initiated by mitochondrial superoxide signaling.

View Article and Find Full Text PDF
Article Synopsis
  • Resistance to MAPK inhibitors in melanoma is linked to lower levels of the tumor suppressor AMBRA1, which predicts poor treatment response.
  • Loss of AMBRA1 triggers phenotype changes and leads to a resistance mechanism that bypasses the usual pathways, increasing reliance on FAK1.
  • Combining MAPK inhibitors with FAK1 inhibitors can effectively prevent resistance in melanomas that have low AMBRA1 expression, highlighting AMBRA1's potential as a predictive marker for treatment efficacy.
View Article and Find Full Text PDF